©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Jun 7, 2005; 11(21): 3245-3249
Published online Jun 7, 2005. doi: 10.3748/wjg.v11.i21.3245
Published online Jun 7, 2005. doi: 10.3748/wjg.v11.i21.3245
Table 1 Patient characteristics.
| Number of patients (%) | |
| Total number of eligible patients | 146 (100) |
| Sex | |
| Male | 87 (60) |
| Female | 59 (40) |
| Age (yr) | |
| Mean | 66 |
| Range | 3686 |
| Performance status (WHO) | |
| 0 | 11 (15) |
| 1 | 53 (72) |
| 2 | 10 (14) |
| Tumor histology | |
| Grade 1 | 24 (16) |
| Grade 2 | 89 (61) |
| Grade 3 | 33 (23) |
| Tumor localization | |
| Rectum | 125 (86) |
| Recto sigmoid | 21 (14) |
| T stage | |
| T1 | 6 (4) |
| T2 | 26 (18) |
| T3 | 94 (64) |
| T4 | 20 (14) |
| Dukes | |
| A | 26 (18) |
| B | 85 (58) |
| C | 25 (17) |
| D | 10 (7) |
| N stage | |
| 0 | 98 (67) |
| 1 | 26 (18) |
| 2 | 22 (15) |
| Primary tumor | 135 (93) |
| Recurrent tumor | 11 (8) |
| Radiotherapy | |
| Given to N patients (%) | 91 (62) |
| Median dose (range) Gy1 | 50 (4867) |
- Citation: Salminen E, Palmu S, Vahlberg T, Roberts PJ, Söderström KO. Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer. World J Gastroenterol 2005; 11(21): 3245-3249
- URL: https://www.wjgnet.com/1007-9327/full/v11/i21/3245.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i21.3245